Non Stimulant Medication for ADHD and How the Options Compare

Non-stimulant medications for ADHD work by raising norepinephrine availability or acting on alpha-2 receptors in the brain, rather than producing the rapid dopamine rise stimulants create. The five commonly used options are atomoxetine (Strattera), viloxazine extended-release (Qelbree), guanfacine extended-release (Intuniv), clonidine extended-release (Kapvay) and bupropion (Wellbutrin), which is used off-label. All of them are taken every day, started low and increased gradually, and all take roughly four to eight weeks to reach full effect. Once effective, they cover symptoms around the clock instead of across a limited daily window.

The sections ahead explain how each option works, which symptom patterns each one suits, what the first eight weeks look like, how non-stimulants compare with stimulants, and when the two get combined.

What Is a Non-Stimulant Medication for ADHD?

A non-stimulant medication for ADHD is a daily medication that improves attention, impulse control and emotional regulation without acting as a central nervous system stimulant. Daily use is the defining rule. Rules of this kind matter because non-stimulants build to a steady level in the body, so skipping days undoes the progress rather than simply shortening a day's coverage.

Coverage is the second defining feature. Once a non-stimulant reaches an effective level, it works 24 hours a day, including early mornings, evenings and weekends, which is when many families feel the gap in stimulant coverage most sharply. Sharp gaps at those hours are one of the main reasons providers reach for this category.

This category also reaches a large group. The Centers for Disease Control and Prevention reports that over 6 million children in the U.S. have been diagnosed with ADHD, and adult diagnoses continue to climb as recognition improves. Improved recognition is why our ADHD treatment covers children, teens and adults rather than one age group.

How Do Non-Stimulant ADHD Medications Work?

Non-stimulant ADHD medications work through two main mechanisms: blocking the reuptake of norepinephrine, or stimulating alpha-2 adrenergic receptors in the prefrontal cortex. The prefrontal cortex handles planning, attention, working memory and impulse control. Impulse control and attention improve as signaling in that region steadies, which happens over weeks rather than hours.

Hours versus weeks is the core difference from stimulants. Atomoxetine and viloxazine are norepinephrine reuptake inhibitors, guanfacine and clonidine are alpha-2 agonists that support prefrontal regulation through a separate pathway, and bupropion blocks reuptake of both norepinephrine and dopamine, which puts its mechanism closest to a stimulant without being one.

Are Non-Stimulant ADHD Medications Controlled Substances?

Non-stimulant ADHD medications are not Schedule II controlled substances. The clinician guidance published by Lurie Children's Hospital notes that non-stimulants are Schedule V medications while stimulants are Schedule II. Scheduling reflects abuse potential, and non-stimulants carry essentially none.

No meaningful abuse potential makes this category the standard choice when a personal or family history of substance use is part of the picture. Picture completeness matters in every one of these decisions, which is why the choice belongs in a conversation with a prescriber rather than a search result.

What Are the Non-Stimulant ADHD Medications?

The non-stimulant ADHD medications are atomoxetine, viloxazine extended-release, guanfacine extended-release, clonidine extended-release and bupropion, which is prescribed off-label. Off-label means a medication is used for a condition outside its formal approval where evidence supports it. Evidence supports all five in ADHD, though the strength of that evidence and the approved age ranges differ.

Differences across these options are easiest to see side by side. The approval years, age ranges and onset timelines below follow FDA labeling and the clinician guidance published by Lurie Children's Hospital.

MedicationClassFDA Status for ADHDTime to Full EffectWhat It Tends to Help MostAtomoxetine (Strattera)Norepinephrine reuptake inhibitorApproved from age 6, including adults4 to 8 weeks, sometimes longerCore inattention and impulsivity, with co-occurring anxietyViloxazine ER (Qelbree)Norepinephrine reuptake inhibitorApproved for ages 6 to 17 in 2021, adults in 20222 to 4 weeks for first effectsCore symptoms, with a faster start than atomoxetineGuanfacine ER (Intuniv)Alpha-2A adrenergic agonistApproved in 2009 for ages 6 to 17, off-label in adults2 to 4 weeksHyperactivity, impulsivity and emotional reactivityClonidine ER (Kapvay)Alpha-2 adrenergic agonistApproved in 2010 for ages 6 to 17, off-label in adults2 to 4 weeksHyperactivity, tics and sleep-onset difficultyBupropion (Wellbutrin)Norepinephrine-dopamine reuptake inhibitorOff-label for ADHD, approved as an antidepressant2 to 6 weeksADHD alongside depression

What Is Atomoxetine (Strattera)?

Atomoxetine is a selective norepinephrine reuptake inhibitor and the first non-stimulant the FDA approved for ADHD, in 2002. Approval that early gave it the deepest research base in the category. Research depth shows in the numbers: Lurie Children's reports effect sizes of 0.6 to 1.3 against placebo on core ADHD symptoms at 6 to 18 weeks, across males and females, children and adolescents, and patients with other conditions alongside ADHD.

Alongside those gains comes a slow build. Initial responses sometimes appear within a week, with a median of 23 days in one six-week study, and the full response often strengthens past three months. Three months is longer than most people expect, which is why setting the timeline correctly at the start matters more with this medication than with almost any other.

What Is Viloxazine ER (Qelbree)?

Viloxazine extended-release is a norepinephrine reuptake inhibitor approved for ADHD in children and adolescents aged 6 to 17 in 2021, with approval extended to adults in 2022. Extension to adults made it the newest option in this category. Newness comes with less long-term data and, for many patients, a faster start.

Faster starts show up in direct comparison. A retrospective head-to-head study found that 87 percent of adults on viloxazine ER reported a positive response at two weeks, compared with 13 percent on atomoxetine. Patients who cannot tolerate a long wait often start here for that reason, and the capsule can be opened and sprinkled on food for children who struggle to swallow pills.

What Is Guanfacine ER (Intuniv)?

Guanfacine extended-release is an alpha-2A adrenergic agonist approved for ADHD in 2009 for ages 6 to 17, as monotherapy or as augmentation alongside a stimulant. Augmentation is where it appears most often in practice. Practice patterns follow its strengths, which lean toward hyperactivity, impulsivity and emotional reactivity rather than pure inattention.

Reactivity and blood pressure respond to the same receptors, which is worth knowing. Guanfacine ER lowers pulse by roughly 3 to 4 beats per minute and blood pressure by about 1 to 2 mm Hg, so prescribers check both at follow-up visits. It also takes two to four weeks for full effect and then provides 24-hour coverage, and Lurie Children's notes it may be an appropriate first-line choice for ADHD symptoms in patients with autism spectrum disorder.

What Is Clonidine ER (Kapvay)?

Clonidine extended-release is an alpha-2 adrenergic agonist approved for ADHD in 2010 for ages 6 to 17, also as monotherapy or alongside a stimulant. Alongside guanfacine it shares a mechanism and differs in feel. Feeling more sedating is the practical difference, which turns into an advantage when sleep is part of the problem.

Sleep problems and tics both come up frequently in ADHD, and clonidine is often chosen when either accompanies the attention symptoms. Immediate-release forms of both alpha agonists last only about four to six hours per dose, which is why the extended-release versions became the standard for daytime ADHD coverage.

Is Wellbutrin Used for ADHD?

Yes, bupropion (Wellbutrin) is used off-label for ADHD, and it blocks reuptake of both norepinephrine and dopamine. Dopamine involvement puts its mechanism closer to a stimulant than any other non-stimulant, without controlled-substance status. Status aside, its clearest role is in people carrying two diagnoses.

Two diagnoses at once is common, and one medication addressing both simplifies a plan considerably. Bupropion is the option most often considered when ADHD sits alongside depression, and it typically takes two to six weeks to show ADHD benefit.

What Is the Most Effective Non-Stimulant ADHD Med?

Atomoxetine is the most effective non-stimulant ADHD medication by weight of evidence, though viloxazine ER often works faster and the alpha agonists suit different symptom patterns better. Evidence weight favors atomoxetine clearly. A Lancet Psychiatry network meta-analysis of adult ADHD treatments identified stimulants and atomoxetine as the most efficacious pharmacological options for core symptoms, and a systematic review of 15 randomized controlled trials in adults found atomoxetine significantly better than placebo with a moderate effect size.

Moderate effect across a population says little about any one person. Symptom profile, other conditions, tolerability and age all shift the answer, which is the work we do during psychiatric care rather than something a ranking can settle.

Which Non-Stimulant Works Best for Inattentive ADHD?

Atomoxetine and viloxazine ER work best for inattentive ADHD, because norepinephrine reuptake inhibitors target attention and focus more directly than the alpha agonists do. Alpha agonists lean toward hyperactivity, impulsivity and emotional regulation, and they are generally less effective for pure inattention. Inattentive presentations are also the ones most often missed in childhood, which is why so many adults arrive for a first evaluation in their thirties or forties.

Forty-year-old first diagnoses are common enough that the pattern is familiar: years of disorganization and missed deadlines interpreted as a character problem rather than a treatable condition.

Which Non-Stimulant Works Best for ADHD With Anxiety?

Atomoxetine and guanfacine ER work best for ADHD with anxiety, since neither carries the risk of worsening anxious symptoms that stimulants sometimes bring. Bringing down two sets of symptoms at once is the goal here. Goals of that kind favor atomoxetine, which has evidence for anxiety symptoms alongside ADHD in children and adolescents, and guanfacine, whose calming effect helps with emotional reactivity.

Reactivity and worry often look alike from the outside, and telling them apart changes the plan, which is the distinction covered in our comparison of ADHD and anxiety.

Either way, treating the anxiety and the attention symptoms inside one plan produces better results than running two unconnected plans.

Are Non-Stimulants Different for Children and Adults?

Yes, non-stimulants differ by age in their approvals rather than in how they work. Atomoxetine and viloxazine ER carry FDA approval for both children from age 6 and adults. Adults receive guanfacine ER and clonidine ER off-label, since both carry approvals only for ages 6 to 17, and bupropion is off-label for ADHD at every age.

Age also changes what gets monitored. Height and weight get tracked in children on atomoxetine, while blood pressure and pulse get tracked at every age on the alpha agonists.

How Long Do Non-Stimulant ADHD Medications Take to Work?

Non-stimulant ADHD medications take four to eight weeks to reach full effect, with alpha agonists often showing benefit in two to four weeks and atomoxetine taking the longest. Taking the longest is not the same as working least. Working least would show in the outcome data, and atomoxetine's outcome data is the strongest in the category.

Strength builds on a predictable arc:

1. Weeks 1 to 2: little obvious change, with early side effects such as nausea or drowsiness more noticeable than benefit.
2. Weeks 2 to 4: first signs of improvement, often reported by family or coworkers before the patient notices.
3. Weeks 3 to 4: alpha agonists reach full effect, and bupropion usually shows its ADHD benefit.
4. Weeks 4 to 6: viloxazine ER typically reaches its full effect, and dose adjustments are common here.
5. Weeks 6 to 8: atomoxetine reaches full effect for most patients.
6. Months 2 to 3: gains on atomoxetine often continue strengthening well past the eight-week mark.

Marking the eight-week point matters because a pooled analysis of six randomized placebo-controlled trials covering 618 patients found that response at four weeks predicts response at six to nine weeks, which gives a prescriber an early read without abandoning a trial too soon. Abandoning too soon is the single most common reason a workable medication gets written off, and it is why we schedule close follow-up through medication management during the first two months. Patients we follow across South Florida often tell us the structured check-ins are what kept them in the trial long enough to see the benefit.

How Do You Know a Non-Stimulant Is Working?

You know a non-stimulant is working when tasks start finishing, the day holds together without a crash, and the people around you notice before you do. Noticing from the outside first is typical with this category, because the change is gradual and the baseline shifts quietly. Quiet shifts are easier to catch with a simple log of attention, mood, sleep and appetite kept during the first eight weeks.

Logging turns impressions into information a provider can act on, and reviewing it at a structured medication check is how dose decisions get made on evidence rather than memory.

What Is the Downside of Strattera?

The downsides of Strattera are its slow onset and its early side effects, which commonly include nausea, decreased appetite, drowsiness, dry mouth and small increases in blood pressure and pulse. Pulse and pressure get checked at follow-up visits, along with height and weight in children. Children and teens taking atomoxetine or viloxazine should also be watched for mood changes early in treatment, since both carry an FDA warning about suicidal thoughts in young people, and any change should be reported to the prescriber promptly.

Prompt reporting handles most of these issues well. Nausea often eases with gradual dose increases and taking the medication with food, and atomoxetine has one clear advantage at the other end: it has no documented discontinuation syndrome and does not need to be tapered.

Why Should Guanfacine and Clonidine Be Stopped Gradually?

Guanfacine and clonidine should be stopped gradually because abrupt discontinuation can cause rebound hypertension, a sharp rise in blood pressure. Blood pressure rises because these medications lower it while they are in the system, and removing them suddenly releases that effect all at once. All-at-once changes are avoidable with a taper planned by the prescriber.

Planned tapers also apply after missed doses. Lurie Children's guidance notes that one or two missed doses are usually fine, while stopping for more than two or three days generally calls for restarting at a lower dose to avoid heavy sedation.

How Do Non-Stimulants Compare to Stimulants?

Non-stimulants build over weeks and cover symptoms around the clock, while stimulants act within hours and cover a limited daily window. Windows and coverage shape the daily experience more than anything else. Anything else being equal, the decision usually comes down to which pattern fits a person's life and health history.

The practical differences break down like this:

• Onset: hours to days for stimulants, four to eight weeks for most non-stimulants.
• Coverage: a limited daily window for stimulants, 24 hours for non-stimulants once effective.
• Scheduling: Schedule II for stimulants, Schedule V for non-stimulants.
• Abuse potential: present with stimulants, essentially absent with non-stimulants.
• Anxiety: sometimes worsened by stimulants, neutral or helped by several non-stimulants.
• Rebound: an afternoon dip is possible with shorter-acting stimulants and absent with non-stimulants.
• Average effectiveness on core symptoms: higher for stimulants across populations.

Across populations is the key qualifier in that last line, because individual response varies widely in both directions.

Do Non-Stimulants Work as Well as Stimulants?

Non-stimulants work less well than stimulants on average for core ADHD symptoms, and they work better than stimulants for a meaningful share of individual patients. Patients in that share include people whose anxiety worsens on a stimulant, people with cardiac considerations, and people with a substance use history. History of this kind makes non-stimulants the appropriate first choice rather than a fallback.

Falling back is not the only route into this category either. Compass Behavioral Health, citing clinical research, notes that roughly 30 percent of adults with ADHD do not achieve adequate symptom control on stimulants or cannot tolerate the side effects, which is a large group arriving at non-stimulants by necessity.

Is Strattera Safer Than Adderall?

Strattera carries no abuse potential and no controlled-substance scheduling, which makes it the safer choice for people with a substance use history or certain cardiac concerns. Concerns of each kind get weighed individually, since both medications carry their own side-effect profiles and neither is universally safer. Universal safety claims do not hold up in medicine, and the honest comparison is about fit.

Fit depends on the full history, including heart conditions, blood pressure, sleep, anxiety, past medication trials and what a person is trying to accomplish day to day.

What Are Some Alternatives to Vyvanse?

The alternatives to Vyvanse include every non-stimulant in this category: atomoxetine, viloxazine ER, guanfacine ER, clonidine ER and off-label bupropion, along with other stimulant formulations. Formulation changes solve some problems, while switching classes solves others. Other problems, such as anxiety that worsens on any stimulant, usually call for the class change rather than a different stimulant.

Class changes also come up during periods when stimulant supply is inconsistent, since non-stimulants are not subject to the same production quotas.

Can You Take a Non-Stimulant and a Stimulant Together?

Yes, non-stimulants and stimulants are commonly combined, and the alpha agonists in particular carry FDA approval for use alongside a stimulant. Approval for combined use exists precisely because the pairing solves a real problem. Real problems in this case look like partial response, or symptoms that return the moment a stimulant wears off.

Wearing off at the wrong hour is the classic reason to add a non-stimulant. A stimulant that works well through the school or work day leaves early mornings and evenings uncovered, and a non-stimulant fills those hours because it works continuously. Continuous coverage can also allow a lower overall stimulant dose in some cases, which is a decision for the prescriber rather than something to adjust independently.

Independent adjustment is risky with any of these medications, which is why combination plans get reviewed on a schedule. Lurie Children's guidance recommends reassessing combination therapy every year or two by slowly tapering the added medication and watching for symptom return.

When Should You Switch From a Stimulant to a Non-Stimulant?

You should consider switching from a stimulant to a non-stimulant when side effects persist, when anxiety worsens, when appetite or growth is affected, when a medical condition makes stimulants inadvisable, or when a substance use history makes a controlled medication the wrong fit. Fit problems of this kind rarely improve with time on the same medication. Time spent waiting them out usually ends in the switch anyway.

Switching also comes up when a stimulant simply stops producing the benefit it once did, and either route starts with a visit rather than a dose change at home.

What Supports ADHD Treatment Beyond Medication?

ADHD treatment beyond medication includes behavioral therapy, executive-function systems, time-management and organizational tools, consistent sleep, and coordination with schools or employers. Coordination matters because ADHD plays out in environments, not just in brain chemistry. Chemistry alone cannot build a planning system or a morning routine.

Routines and systems are what medication makes possible rather than what it replaces. Our behavioral therapy focuses on focus, planning and emotional regulation, and we pair it with practical coaching on time management and organization. We also collaborate with schools or employers when that helps, which is a standard part of treating ADHD in students and working adults alike.

How We Approach ADHD Medication

We start with a comprehensive psychiatric evaluation for children, teens or adults, covering symptom history, prior medication trials, sleep, co-occurring conditions and what daily life actually looks like.

From there we build a plan that may include medication chosen for symptom type and lifestyle needs, behavioral therapy, time-management coaching and organizational tools, collaboration with schools or employers, and faith-aligned care for patients who want it. Patients in Miami Lakes frequently tell us they spent years believing they lacked discipline, and reframing that as a treatable condition is often the turning point. We set goals together, review progress on a schedule, and adjust when the plan stops producing gains.

Frequently Asked Questions

What Is the Newest Non-Stimulant ADHD Medication?

Viloxazine extended-release (Qelbree) is the newest non-stimulant ADHD medication, approved for children and adolescents aged 6 to 17 in 2021 and for adults in 2022. It works as a norepinephrine reuptake inhibitor with some additional serotonergic activity. Many patients notice first effects within two to four weeks, which is faster than atomoxetine typically delivers.

What Happens If You Miss a Dose of a Non-Stimulant?

Missing a single dose of a non-stimulant usually causes no major problem, and missing several days does. Several days off an alpha agonist generally means restarting at a lower dose to avoid heavy sedation, and stopping one abruptly can cause rebound high blood pressure. Atomoxetine has no documented discontinuation syndrome, though consistency still matters because the medication works by maintaining a steady level.

Can ADHD Be Treated Without Medication?

Yes, ADHD can be treated without medication using behavioral therapy, executive-function coaching, structured routines, environmental changes and consistent sleep. Non-medication approaches work best for mild presentations and as support alongside medication for moderate to severe ones. Many adults use both, with medication creating the window in which new systems can actually be built.

Do Non-Stimulants Help With Sleep Problems or Tics?

Yes, the alpha agonists help with sleep problems and tics alongside ADHD symptoms. Clonidine is the more sedating of the two and is sometimes given at bedtime for that reason, while guanfacine tends to be less sedating in its extended-release form. Both are moderately effective for inattention, hyperactivity, impulsivity and tics, which is why they are frequently chosen when more than one of those is present.

Can ADHD Be Diagnosed and Treated Online?

Yes, ADHD can be evaluated and managed online, and non-stimulant medications fit virtual care particularly well because they are not Schedule II substances. Follow-up visits during the titration period also work well remotely, since the main tasks are reviewing symptoms, side effects and any blood pressure readings. Secure virtual visits through telehealth cover evaluations and ongoing follow-up.

When Should You See a Provider About ADHD?

You should see a provider about ADHD when attention, organization, impulsivity or restlessness interferes with work, school, relationships or daily routines over a sustained period. Sustained interference rather than an occasional bad week is the threshold. Anyone unsure which type of provider fits can start by reading when seeing a psychiatrist makes sense.

The Bottom Line

Non-stimulant ADHD medications give people a real alternative when stimulants are not the right fit. Atomoxetine carries the deepest evidence base, viloxazine ER is the newest option and usually the fastest of the group to show effects, guanfacine ER and clonidine ER target hyperactivity, emotional reactivity, tics and sleep, and bupropion suits ADHD alongside depression. All of them are taken daily, increased gradually, and judged at four to eight weeks rather than in the first week.

Patience during that window is what separates a successful trial from an abandoned one. If stimulants have not worked for you or your child, or a non-stimulant has always seemed like the better starting point, we are glad to talk through which option fits the symptom picture. At South Florida Med Group, that starts with a real evaluation rather than a quick prescription, and you can reach us at (786) 860-8844 whenever you are ready.

‍